MedTrace Logo

Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients

NCT01817699 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2019-02-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of anemia correction and vitamin D supplementation in kidney transplant recipients.

Conditions

  • Kidney Transplantation
  • Anemia
  • Vitamin D Deficiency
  • Renal Insufficiency, Chronic

Interventions

OTHER

High Hb target

25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval. Dose and interval will be adjusted according to hemoglobin level and its target.

DIETARY_SUPPLEMENT

cholecalciferol

1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.

Sponsors & Collaborators

  • Chugai Pharmaceutical

    collaborator INDUSTRY

  • Japanese Society for the Promotion of Science

    collaborator OTHER

  • The Japan Kidney Foundation

    collaborator OTHER

  • Roche Diagnostics GmbH

    collaborator INDUSTRY

  • CANDLE-KIT Trial Study Group

    lead OTHER

Principal Investigators

  • Takayuki Hamano, MD, PhD · Department of Inter-Organ Communication Research in Kidney Disease, Osaka University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01817699 on ClinicalTrials.gov